LEO X. LIU, M.D.; SUSAN J. SEWARD, M.D.; CLYDE S. CRUMPACKER, M.D.
To the editor: Many adverse reactions have been reported recently (1-3) to intravenous trimethoprim-sulfamethoxazole, a combination widely used in the therapy for Pneumocystis carinii pneumonia. We report two cases of severe reversible ataxia that developed in patients during such therapy.
Patient 1: A 47-year-old homosexual man with known diffuse lymphadenopathy was admitted with fever, hypoxia, and diffuse interstitial lung infiltrates. The neurologic findings on admission were normal. A bronchoscopic biopsy sample showed P. carinii pneumonia, and treatment with intravenous trimethoprim-sulfamethoxazole, 20 mg/kg · d was begun. The patient developed unsteadiness and falling by day 3 of therapy. Neurologic examination now
Learn more about subscription options.
Register Now for a free account.
LIU LX, SEWARD SJ, CRUMPACKER CS. Intravenous Trimethoprim-Sulfamethoxazole and Ataxia. Ann Intern Med. 1986;104:448. doi: 10.7326/0003-4819-104-3-448_1
Download citation file:
Published: Ann Intern Med. 1986;104(3):448.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only